Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir

Gastroenterology

Volumn 132, Issue 5, 2007, Pages 1767-1777

  Sarrazin, Christoph ^a   Kieffer, Tara L ^b   Bartels, Doug ^b   Hanzelka, Brian ^b   Müh, Ute ^b   Welker, Martin ^a   Wincheringer, Dennis ^a   Zhou, Yi ^b   Chu, Hui May ^b   Lin, Chao ^b   Weegink, Christine ^c   Reesink, Henk ^c   Zeuzem, Stefan ^a   Kwong, Ann D ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b VERTEX PHARMACEUTICALS   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROTEINASE INHIBITOR; TELAPREVIR; UNCLASSIFIED DRUG; VX 950;

ARTICLE; CATALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

EID: 34247594930     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.02.037     Document Type: Article

References (39)

1. Swan T. The hepatitis C virus (HCV) treatment pipeline. In: Harringtong M., and Hugg B. (Eds). What's in the pipeline: new HIV drugs, vaccines, microbicides, HCV and TB treatments in clinical trials (2005), Treatment Action Group, New York
2. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 36 (2002) S35-S46
3. Curry M.P. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 78 (2004) 955-963
4. Purcell R.H. Hepatitis C virus: historical perspective and current concepts. FEMS Microbiol Rev 14 (1994) 181-192
5. Strader D.B., Wright T., Thomas D.L., and Seeff L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
6. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., and Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
7. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
8. Hadziyannis S.J., Sette Jr. H., Morgan T.R., Balan V., Diago M., Marcellin P., Ramadori G., Bodenheimer Jr. H., Bernstein D., Rizzetto M., Zeuzem S., Pockros P.J., Lin A., and Ackrill A.M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 346-355
9. Foster G.R. Past, present, and future hepatitis C treatments. Semin Liver Dis 24 Suppl 2 (2004) 97-104
10. Organization W.H. Global surveillance and control of hepatitis C-report of the WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6 (1999) 35-47
11. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339 (1998) 1485-1492
12. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (1998) 1426-1432
13. Gish R.G. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 57 (2006) 8-13
14. Pawlotsky J.M., and McHutchison J.G. Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003. Hepatology 39 (2004) 554-567
15. McHutchison J.G., Bartenschlager R., Patel K., and Pawlotsky J.M. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 44 (2006) 411-421
16. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., and Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-189
17. Hinrichsen H., Benhamou Y., Wedemeyer H., Reiser M., Sentjens R.E., Calleja J.L., Forns X., Erhardt A., Crönlein J., Chaves R.L., Yong C.L., Nehmiz G., and Steinmann G.G. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127 (2004) 1347-1355
18. Reiser M., Hinrichsen H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., Riba N., Yong C.L., Nehmiz G., and Steinmann G.G. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
19. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S.K., Hussain M., Shah A., Cutler D., Zhang J., and Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon α-2b for genotype 1 non-responders. Gastroenterology (2007) Jan 25; [Epub ahead of print]
20. Perni R.B., Almquist S.J., Byrn R.A., Chandorkar G., Chaturvedi P.R., Courtney L.F., Decker C.J., Dinehart K., Gates C.A., Harbeson S.L., Heiser A., Kalkeri G., Kolaczkowski E., Lin K., Luong Y.P., Rao B.G., Taylor W.P., Thomson J.A., Tung R.D., Wei Y., Kwong A.D., and Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50 (2006) 899-909
21. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., Van Vliet A., van de Wetering de Rooij J., McNair L., Purdy S., Kauffman R., Alam J., and Jansen P.L.M. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 131 (2006) 997-1002
22. Lu L., Pilot-Matias T.J., Stewart K.D., Randolph J.T., Pithawalla R., He W., Huang P.P., Klein L.L., Mo H., and Molla A. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 48 (2004) 2260-2266
23. Lin C., Lin K., Luong Y.P., Rao B.G., Wei Y.Y., Brennan D.L., Fulghum J.R., Hsiao H.M., Ma S., Maxwell J.P., Cottrell K.M., Perni R.B., Gates C.A., and Kwong A.D. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279 (2004) 17508-17514
24. Yi M., Tong X., Skelton A., Chase R., Chen T., Prongay A., Bogen S.L., Saksena A.K., Njoroge F.G., Veselenak R.L., Pyles R.B., Bourne N., Malcolm B.A., and Lemon S.M. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem 281 (2006) 8205-8215
25. Trozzi C., Bartholomew L., Ceccacci A., Biasiol G., Pacini L., Altamura S., Narjes F., Muraglia E., Paonessa G., Koch U., De Francesco R., Steinkuhler C., and Migliaccio G. In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 77 (2003) 3669-3679
26. Sarrazin C., Gärtner B.C., Sizmann D., Babiel R., Mihm U., Hofmann W.P., von Wagner M., and Zeuzem S. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol 44 (2006) 729-737
27. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I.T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., and Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 (2005) 962-973
28. Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39 (1985) 783-791
29. Sarrazin C., Bruckner M., Herrmann E., Rüster B., Bruch K., Roth W.K., and Zeuzem S. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 289 (2001) 150-163
30. Grossman T.H., Kawasaki E.S., Punreddy S.R., and Osburne M.S. Spontaneous cAMP-dependent derepression of gene expression in stationary phase plays a role in recombinant expression instability. Gene 209 (1998) 95-103
31. Lin C., Gates C.A., Rao B.G., Brennan D.L., Fulghum J.R., Luong Y.P., Frantz J.D., Lin K., Ma S., Wei Y.Y., Perni R.B., and Kwong A.D. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 280 (2005) 36784-36791
32. Richman D.D. Antiviral drug resistance. Antiviral Res 71 (2006) 117-121
33. Shafer R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15 (2002) 247-277
34. Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 (2004) 1023-1025
35. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., and Malcolm B.A. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 70 (2006) 28-38
36. Charpentier C., Dwyer D.E., Mammano F., Lecossier D., Clavel F., and Hance A.J. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 78 (2004) 4234-4247
37. Siliciano R.F. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution. Top HIV Med 13 (2005) 96-100
38. Forestier N., Reesink H.W., Weegink C.J., McNair L., Kieffer T.L., Chu H.-M., Purdy S., Jansen P.L.M., and Zeuzem S. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (2007) (in press).
39. Lawitz E., Rodriquez-Torres M., Muir A., Keane J., Kieffer T., McNair L., and McHutchison J. 28 Days of the hepatitis C protease inhibitor VX-950, in combination with peg-interferon-alfa-2a (Pegasys) and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology 131 (2006) 950-951